Welcome to Our Medtech Talk Podcast Channel

Too often we define the Medtech sector by the number of dollars raised, IPOs helped or companies sold. But the focus neglects the very foundation of the sector - the People. Join the Medtech Talk Podcast each week to hear from entrepreneurs, investors and executives who spend their days developing the tools that make sick people well and health care more efficient.



Former VC Nim Shah Dishes on JP Morgan, the Four Horsemen, and What It’s Like Joining a Start-Up

March 30, 2017

 

Hashtag messages don’t often carry deep meanings or life missions, but Nim Shah’s Twitter profile – yes, there’s at least one Medtecher who tweets – pretty much says it all: #devicesforlife. Shah latched himself onto Medtech 20 years ago, joining the prolific team of Alex Brown that produced many who moved Medtech over the next two decades. Shah’s longest stint was at Domain Associates. But now he’s taken his talents to Fractyl Laboratories, one of the more interesting start-ups in Medtech. In this podcast, Shah recounts the trail that led him to Fractyl, shares thoughts on JP Morgan, New England weather, and why Medtech and Biotech took such divergent paths.

 

Nimesh Shah

Chief Business Officer

Fractyl Laboratories

Nimesh Shah is Chief Business Officer of Fractyl. Nimesh brings with him nearly 20 years of venture capital and Wall Street experience specializing in early-stage or growth oriented medical device companies. Prior to joining Fractyl, Nimesh was a partner of Domain Associates, a leading health care venture capital firm, leading that firm’s efforts in medical devices. Previously, Nimesh served in various roles at venture firm Cutlass Capital and investment bank Alex. Brown (now Deutsche Bank). Nimesh received his B.S. in Biomedical Engineering from the Johns Hopkins University.

Meet Our Host, Geoff Pardo

Geoff has been in medtech for over two decades in both operational and investment roles. He is passionate about the industry potential and sharing stories from the front lines of innovation.